Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.50 |
| ▸ | HTR1D | P28221 | 1/20 | 0.49 |
| ▸ | HTR1B | P28222 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | PDE5A | O76074 | 1/20 | 0.46 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.42 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30966945 | 1.00 | SIGMAR1 (0.50) | SIGMAR1HTR1DHTR1BKMT2ASCN9A | |
| SCHEMBL9821937 | 0.84 | SIGMAR1 (0.63) | SIGMAR1KMT2ASCN9ACYP2D6CYP1A2 | |
| SCHEMBL10747554 | 0.82 | S1PR1 (0.43) | SIGMAR1CYP2D6CYP1A2CYP2C19SLC6A2 | |
| SCHEMBL28462489 | 0.81 | CYP2D6 (0.67) | SIGMAR1KMT2ACYP2D6CYP1A2CYP2C19 | |
| SCHEMBL6541752 | 0.81 | L3MBTL1 (0.45) | SIGMAR1HTR1DHTR1BKMT2ACYP2D6 | |
| SCHEMBL2343211 | 0.79 | TSHR (0.59) | SIGMAR1HTR1DHTR1BKMT2ACYP2C19 | |
| SCHEMBL29862183 | 0.79 | SIGMAR1 (0.57) | SIGMAR1KMT2ACYP2D6CYP1A2CYP2C19 | |
| SCHEMBL3232376 | 0.79 | SIGMAR1 (0.57) | SIGMAR1KMT2ACYP2D6CYP1A2CYP2C19 | |
| SCHEMBL9463178 | 0.78 | AOC3 (0.44) | SIGMAR1HTR1DHTR1BKMT2ACYP2D6 | |
| Hydrochloric Acid SCHEMBL3792219 | 0.77 | TSHR (0.58) | SIGMAR1HTR1DHTR1BKMT2ACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110381955-A | For preventing and treating the pharmaceutical composition containing adenosine derivative of glaucoma | 未来制药有限公司 | 2019-10-25 | — | — | CN | disclosed |
| CN-109906083-A | Pharmaceutical composition containing adenosine derivative for preventing and treating non-alcoholic steatohepatitis, hepatic fibrosis and liver cirrhosis | 未来制药有限公司 | 2019-06-18 | — | — | CN | disclosed |
| CN-104969406-A | Electrolyte solution for electrochemical device and electrochemical device | WAKO PURE CHEM IND LTD | 2015-10-07 | — | — | CN | disclosed |
| EP-2142549-B1 | ADENOSINE DERIVATIVES, METHOD FOR THE SYNTHESIS THEREOF, AND THE PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF THE INFLAMMATORY DISEASES CONTAINING THE SAME AS AN ACTIVE INGREDIENT | FM THERAPEUTICS CO LTD (KR) | 2013-07-10 | — | — | EP | disclosed |
| US-20100137577-A1 | ADENOSINE DERIVATIVES, METHOD FOR THE SYNTHESIS THEREOF, AND THE PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF THE INFLAMMATORY DISEASES CONTAINING THE SAME AS AN ACTIVE INGREDIENT | FUTURE MEDICINE CO., LTD. (KR) | 2010-06-03 | — | — | US | disclosed |
| EP-2142549-A1 | ADENOSINE DERIVATIVES, METHOD FOR THE SYNTHESIS THEREOF, AND THE PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF THE INFLAMMATORY DISEASES CONTAINING THE SAME AS AN ACTIVE INGREDIENT | FM Therapeutics Co., Ltd. (KR) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008108508-A1 | ADENOSINE DERIVATIVES, METHOD FOR THE SYNTHESIS THEREOF, AND THE PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF THE INFLAMMATORY DISEASES CONTAINING THE SAME AS AN ACTIVE INGREDIENT | FM THERAPEUTICS CO., LTD. (KR) | 2008-09-12 | — | — | WO | disclosed |
| US-5492954-A | STABILIZE LUBRICANTS AND SYNTHETIC POLYMERS AGAINST THE DELETERIOUS EFFECTS OF OXYGEN AND HEAT | CIBA-GEIGY CORPORATION (US) | 1996-02-20 | — | — | US | disclosed |
| US-5391808-A | Lubricant and synthetic polymer additives for heat and oxidation resistance | CIBA-GEIGY CORPORATION (US) | 1995-02-21 | — | — | US | disclosed |
| EP-0585202-A1 | N,N'-alkenylene amine/mercaptotolyl-imidazole blends as high temperature antioxidants for elastomers | CIBA-GEIGY AG (CH) | 1994-03-02 | — | — | EP | disclosed |
| US-5283367-A | Antioxidants for lubricants and polymers | CIBA-GEIGY CORPORATION (US) | 1994-02-01 | — | — | US | disclosed |
| US-5240976-A | For automobile, wire and cable uses | CIBA-GEIGY CORPORATION (US) | 1993-08-31 | — | — | US | disclosed |
| EP-0514333-A2 | Substituted 1,4-diamino-2-butene stabilizers and stabilized compositions | CIBA-GEIGY AG (CH) | 1992-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137577-A1 | ADENOSINE DERIVATIVES, METHOD FOR THE SYNTHESIS THEREOF, AND THE PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF THE INFLAMMATORY DISEASES CONTAINING THE SAME AS AN ACTIVE INGREDIENT | ADORA3, ADORA2A, ADORA1 | SIGMAR1 1330/4885HTR1D 1054/4885HTR1B 719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.